Overview
-$4.7MNet income, fiscal 20252
- TickerMENS on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersE91
- Incorporated inCayman Islands3
- Business address23F-3, No.95, Sec. 1, Xintai 5Th Rd., Xizhi Dist., New Taipei City3
- Filer categoryNon-accelerated filer, Emerging growth company3
See how the biggest companies compare on our leaderboards
Harbour Place, 103 South Church Street, George Town, P. O. Box 10240, Grand Cayman KY1 1002, Cayman Islands.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | -$813.0K | -$927.0K | -$1.1M |
| Selling and marketing | -$45.0K | -$44.0K | -$47.0K |
| General and administrative | -$1.7M | -$1.1M | -$1.7M |
| Total operating expenses | -$2.6M | -$2.1M | -$2.8M |
| Loss from operations | -$2.6M | -$2.1M | -$2.8M |
| Interest income | $610.0K | $7.0K | $56.0K |
| Interest expenses | -$2.5M | -$1.0M | -$757.0K |
| Other (losses) gains, net | -$135.0K | $65.0K | -$902.0K |
| Total other expenses, net | -$2.1M | -$963.0K | -$1.6M |
| Loss before income tax | -$4.7M | -$3.0M | -$4.4M |
| Net loss | -$4.7M | -$3.0M | -$4.4M |
| Foreign currency translation adjustments, net of nil tax | -$439.0K | $573.0K | -$42.0K |
| Total comprehensive loss | -$5.1M | -$2.4M | -$4.4M |
| Basic (in Dollars per share) | -$0.06 | -$0.04 | -$0.06 |
| Diluted (in Dollars per share) | -$0.06 | -$0.04 | -$0.06 |
| Basic (in Shares) | 73.0M shares | 71.6M shares | 71.6M shares |
| Diluted (in Shares) | 73.0M shares | 71.6M shares | 71.6M shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash | $1.2M | $98.0K | $177.0K | |
| Restricted cash | $3.0K | $3.0K | ||
| Prepayments and other current assets | $854.0K | $105.0K | ||
| Loan receivable from shareholder | $13.5M | |||
| Total current assets | $15.5M | $206.0K | ||
| Property and equipment, net | $3.1M | $3.0M | ||
| Operating right-of-use assets | $66.0K | $137.0K | ||
| Deferred offering costs | $934.0K | |||
| Restricted asset | $2.1M | $2.0M | ||
| Other non-current assets | $6.0K | $6.0K | ||
| Total non-current assets | $5.2M | $6.2M | ||
| TOTAL ASSETS | $20.8M | $6.4M | ||
| Short-term bank loans | $7.7M | $7.2M | ||
| Notes and accounts payable | $2.0K | $3.0K | ||
| Accrued expenses | $1.0M | $1.2M | ||
| Accrued expenses due to related parties | $281.0K | $147.0K | ||
| Current portion of long-term bank loans | $571.0K | $57.0K | ||
| Operating lease liabilities due to related parties-current | $81.0K | $159.0K | ||
| Accrued liabilities - guarantee obligation | $21.6M | |||
| Other current liabilities | $3.4M | $3.3M | ||
| Other current liabilities due to related parties | $68.0K | $41.0K | ||
| Total current liabilities | $34.8M | $12.1M | ||
| Long-term loan from third parties | $2.4M | $3.1M | ||
| Long-term bank loans, net of current portion | $1.6M | $2.0M | ||
| Operating lease liabilities due to related parties non-current | $26.0K | $16.0K | ||
| Other non-current liabilities | $60.0K | $58.0K | ||
| Other non-current liabilities due to related parties | $628.0K | $628.0K | ||
| Guarantee liabilities | $19.4M | |||
| Total non-current liabilities | $10.9M | $30.8M | ||
| TOTAL LIABILITIES | $45.7M | $42.9M | ||
| Ordinary shares, $0.00001 par value; 5,000,000 thousand shares authorized; 73,361 thousand and 76,028 thousand shares issued and outstanding as of December 31, 2024 and 2025, respectively | $1.0K | $1.0K | ||
| Additional paid-in capital | $28.5M | $11.8M | ||
| Treasury shares, 1,794 thousand shares as of December 31, 2024 and 2025, respectively | -$16.4M | -$16.4M | ||
| Accumulated deficit | -$37.8M | -$33.1M | -$30.1M | |
| Accumulated other comprehensive income | $682.0K | $1.1M | ||
| Total shareholders deficit | -$24.9M | -$36.5M | -$34.1M | -$29.6M |
| TOTAL LIABILITIES AND SHAREHOLDERS DEFICIT | $20.8M | $6.4M | ||
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, shares authorized (in Shares) | 5.0B shares | 5.0B shares | ||
| Ordinary shares, shares issued (in Shares) | 76.0M shares | 73.4M shares | ||
| Ordinary shares, shares outstanding (in Shares) | 76.0M shares | 73.4M shares | ||
| Treasury shares (in Shares) | 1.8M shares | 1.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash | $1.2M | $98.0K | $177.0K | |
| Restricted cash | $3.0K | $3.0K | ||
| Prepayments and other current assets | $854.0K | $105.0K | ||
| Loan receivable from shareholder | $13.5M | |||
| Total current assets | $15.5M | $206.0K | ||
| Property and equipment, net | $3.1M | $3.0M | ||
| Operating right-of-use assets | $66.0K | $137.0K | ||
| Deferred offering costs | $934.0K | |||
| Restricted asset | $2.1M | $2.0M | ||
| Other non-current assets | $6.0K | $6.0K | ||
| Total non-current assets | $5.2M | $6.2M | ||
| TOTAL ASSETS | $20.8M | $6.4M | ||
| Short-term bank loans | $7.7M | $7.2M | ||
| Notes and accounts payable | $2.0K | $3.0K | ||
| Accrued expenses | $1.0M | $1.2M | ||
| Accrued expenses due to related parties | $281.0K | $147.0K | ||
| Current portion of long-term bank loans | $571.0K | $57.0K | ||
| Operating lease liabilities due to related parties-current | $81.0K | $159.0K | ||
| Accrued liabilities - guarantee obligation | $21.6M | |||
| Other current liabilities | $3.4M | $3.3M | ||
| Other current liabilities due to related parties | $68.0K | $41.0K | ||
| Total current liabilities | $34.8M | $12.1M | ||
| Long-term loan from third parties | $2.4M | $3.1M | ||
| Long-term bank loans, net of current portion | $1.6M | $2.0M | ||
| Operating lease liabilities due to related parties non-current | $26.0K | $16.0K | ||
| Other non-current liabilities | $60.0K | $58.0K | ||
| Other non-current liabilities due to related parties | $628.0K | $628.0K | ||
| Guarantee liabilities | $19.4M | |||
| Total non-current liabilities | $10.9M | $30.8M | ||
| TOTAL LIABILITIES | $45.7M | $42.9M | ||
| Ordinary shares, $0.00001 par value; 5,000,000 thousand shares authorized; 73,361 thousand and 76,028 thousand shares issued and outstanding as of December 31, 2024 and 2025, respectively | $1.0K | $1.0K | ||
| Additional paid-in capital | $28.5M | $11.8M | ||
| Treasury shares, 1,794 thousand shares as of December 31, 2024 and 2025, respectively | -$16.4M | -$16.4M | ||
| Accumulated deficit | -$37.8M | -$33.1M | -$30.1M | |
| Accumulated other comprehensive income | $682.0K | $1.1M | ||
| Total shareholders deficit | -$24.9M | -$36.5M | -$34.1M | -$29.6M |
| TOTAL LIABILITIES AND SHAREHOLDERS DEFICIT | $20.8M | $6.4M | ||
| Ordinary shares, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Ordinary shares, shares authorized (in Shares) | 5.0B shares | 5.0B shares | ||
| Ordinary shares, shares issued (in Shares) | 76.0M shares | 73.4M shares | ||
| Ordinary shares, shares outstanding (in Shares) | 76.0M shares | 73.4M shares | ||
| Treasury shares (in Shares) | 1.8M shares | 1.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$4.7M | -$3.0M | -$4.4M |
| Depreciation | $100.0K | $120.0K | $127.0K |
| Noncash operating lease expenses | $176.0K | $170.0K | $175.0K |
| Fair value changes in the guarantee liabilities | -$19.4M | $591.0K | $379.0K |
| Gain on disposal of short-term investments | -$3.0K | ||
| Prepayments and other current assets | -$749.0K | -$8.0K | -$2.0K |
| Notes and accounts payable | -$1.0K | $1.0K | -$2.0K |
| Accrued liabilities guarantee obligation | $21.6M | $0 | |
| Accrued expenses | -$159.0K | $76.0K | $254.0K |
| Accrued expenses due to related parties | $134.0K | $92.0K | $42.0K |
| Operating lease liabilities due to related parties | -$130.0K | -$124.0K | -$128.0K |
| Other current liabilities | $10.0K | -$1.5M | $878.0K |
| Other current liabilities due to related parties | $27.0K | $20.0K | $17.0K |
| Other non-current liabilities | -$1.0K | $59.0K | |
| Net cash used in operating activities | -$3.0M | -$3.6M | -$2.6M |
| Purchases of short-term investments | -$16.9M | ||
| Proceeds from disposal of short-term investments | $16.9M | ||
| Proceeds from maturity of time deposits | $95.0K | ||
| Loan to a shareholder | -$15.0M | ||
| Repayment from shareholder | $1.5M | ||
| Net cash provided by (used in) investing activities | -$13.5M | $95.0K | |
| Payments of deferred offering costs | -$114.0K | -$213.0K | -$445.0K |
| Proceeds from short-term bank loans | $23.1M | $9.2M | $9.8M |
| Repayment of short-term bank loans | -$22.9M | -$9.4M | -$9.1M |
| Proceeds from issuance of ordinary shares | $17.8M | ||
| Proceeds of loan from related parties | $1.4M | $2.4M | $2.0M |
| Repayments of loan from related parties | -$800.0K | -$120.0K | |
| Repayment of loan from third party | -$700.0K | ||
| Repayments of long-term bank loans | -$60.0K | -$71.0K | -$123.0K |
| Net cash provided by financing activities | $17.6M | $2.0M | $2.0M |
| Effects of exchange rate changes on cash and restricted cash | -$8.0K | -$7.0K | -$54.0K |
| NET (DECREASE)INCREASE IN CASH AND RESTRICTED CASH | $1.1M | -$1.6M | -$532.0K |
| Interest paid | $337.0K | $223.0K | $104.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Jyong Biotech Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Jyong Biotech Ltd.
- Perfect Mind Co., Ltd Filed SCHEDULE 13D on Jyong Biotech Ltd., latest Apr 24, 2026
- Jyong Biotech Ltd. E9
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Jyong Biotech Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $4.8M2 Dec 31, 2025 | $4.6M2 Dec 31, 2024 | +4.5% |
| Accumulated depreciation | $1.7M2 Dec 31, 2025 | $1.6M2 Dec 31, 2024 | +10.7% |
| Property and equipment, net | $3.1M2 Dec 31, 2025 | $3.0M2 Dec 31, 2024 | +1.3% |
| Operating-lease assets (leased space) | $66.0K2 Dec 31, 2025 | $137.0K2 Dec 31, 2024 | −51.8% |
Leadership
Who has led Jyong Biotech Ltd., and when. Pick a name to see everywhere that person has worked.
Chief executive
- Chief executive officerFu-Feng Kuo Apr 8, 2026 to now5
Board members and other officers (5)
- Board memberFeng-Lin Hsu Apr 1, 2026 to now6
- Board memberHung-Shu Fan Apr 1, 2026 to now7
- Board memberMing Tsan Hsu Apr 1, 2026 to now8
- Board memberPang-Chieh Chi Apr 1, 2026 to now9
- Board memberFu-Feng Kuo Apr 8, 2026 to now5
Timeline
- Apr 8, 2026New chief executive Fu-Feng Kuo becomes CEO5
Filings
73 filings to the SEC since October 2021: 1 annual reports, 7 insider forms, 1 large holders, 64 other. The latest 20:
- May 15, 202620-F ANNUAL REPORT EDGAR
- Apr 29, 2026NT 20-F NOTIFICATION OF LATE FILING EDGAR
- Apr 24, 2026SCHEDULE 13D EDGAR
- Apr 14, 20263 PRIMARY DOCUMENT EDGAR
- Apr 8, 20263 PRIMARY DOCUMENT EDGAR
- Apr 1, 20263 PRIMARY DOCUMENT EDGAR
- Apr 1, 20263 PRIMARY DOCUMENT EDGAR
- Apr 1, 20263 PRIMARY DOCUMENT EDGAR
- Apr 1, 20263 PRIMARY DOCUMENT EDGAR
- Apr 1, 20263 PRIMARY DOCUMENT EDGAR
- Feb 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jan 9, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 30, 2025SP 15D2 EDGAR
- Jun 20, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jun 18, 2025424B4 PROSPECTUS EDGAR
- Jun 16, 2025EFFECT EDGAR
- Jun 16, 2025CERT EDGAR
- Jun 12, 20258-A12B FOR REGISTRATION OF CERTAIN CLASSES EDGAR
- Jun 12, 2025CORRESP EDGAR
- Jun 12, 2025CORRESP EDGAR
The 73 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Perfect Mind Co., LtdSCHEDULE 13D, 1 filing Apr 24, 202610
SEC filer profile
How Jyong Biotech Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARJyong Biotech Ltd.1
- CIK0001954488
- Filer statusNon-accelerated filer an emerging growth company; not a shell company4
- Incorporated inCayman Islands4
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address23F-3, No.95, Sec. 1, Xintai 5Th Rd., Xizhi Dist., New Taipei City, Taiwan1
- Phone(8862) 273252051
- Shares outstanding76,027,667 shares as of Dec 31, 20254
- AuditorWWC, P.C, San Mateo, California PCAOB ID 1171; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMar 16, 20231
- Filings73 in all: CORRESP (15), UPLOAD (13), F-1/A (12), 3 (7), FWP (4), 6-K (3), DRS/A (2), DRSLTR (2)1
All 20 form types
EFFECT (2), F-1 (2), POS AM (2), 20-F (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), NT 20-F (1), RW (1), SCHEDULE 13D (1), SP 15D2 (1)
- Latest filingsAnnual report (20-F) May 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary shares, par value US$0.00001 per share | MENS | Nasdaq |
From the cover page of the 20-F filed May 15, 2026 (Section 12(b) of the Exchange Act).4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5SEC EDGARFu-Feng Kuo, Chief executive officer
- 6SEC EDGARFeng-Lin Hsu, Board member
- 7SEC EDGARHung-Shu Fan, Board member
- 8SEC EDGARMing Tsan Hsu, Board member
- 9SEC EDGARPang-Chieh Chi, Board member
- 10